Jaheli Fuenmayor
Overview
Explore the profile of Jaheli Fuenmayor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
11
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Diaz-Solano D, Fuenmayor J, Montano R
Blood Transfus
. 2017 Jul;
16(2):200-208.
PMID: 28686149
Background: Anti-RhD antibodies (anti-D) are important in the prophylaxis of haemolytic disease of the foetus and newborn (HDFN) due to RhD incompatibility. Current preparations of anti-D are sourced from hyperimmune...
2.
Perez-Witzke D, Miranda-Garcia M, Suarez N, Becerra R, Duque K, Porras V, et al.
Immunology
. 2016 Jan;
148(1):40-55.
PMID: 26801967
Immunoglobulin E-mediated allergy and certain autoimmune diseases are characterized by the presence of a T helper type 2 (Th2) immune response and allergen-specific or self-reactive IgE. Soluble CD23 (sCD23) is...
3.
Marchi R, Garmendia J, Kanzler D, Fuenmayor J
Blood Coagul Fibrinolysis
. 2014 Jan;
26(3):239-45.
PMID: 24418942
The antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence of antibodies against β2-Glycoprotein I (aβ2-GPI), cardiolipin (aCL) and lupus anticoagulant combined with venous or arterial thrombosis and/or...
4.
Fuenmayor J, Montano R
Cancers (Basel)
. 2013 Nov;
3(3):3370-93.
PMID: 24212958
The relative success of monoclonal antibodies in cancer immunotherapy and the vast manipulation potential of recombinant antibody technology have encouraged the development of novel antibody-based antitumor proteins. Many insightful reagents...
5.
Fuenmayor J, Perez-Vazquez K, Perez-Witzke D, Penichet M, Montano R
Mol Cancer Ther
. 2010 Aug;
9(8):2175-85.
PMID: 20682652
Treatment of human epidermal growth factor receptor 2 (HER2/neu)-expressing breast cancer patients with a monoclonal antibody (mAb) directed against HER2/neu improves the outcome of chemotherapy. In cases in which remission...